These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 657108

  • 1. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
    Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB.
    Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
    [Abstract] [Full Text] [Related]

  • 2. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
    Lieberman R, Wybran J, Epstein W.
    Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
    [Abstract] [Full Text] [Related]

  • 3. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM, Cerni C, Micksche M.
    Oncology; 1977 Mar; 34(5):229-33. PubMed ID: 917456
    [Abstract] [Full Text] [Related]

  • 4. Effect of BCG (Tice strain) on primary sensitization to 2,4-dinitrochlorobenzene and on established delayed hypersensitivity in human malignant melanoma.
    Mavligit GM, Gutterman JU, Hersh EM.
    J Natl Cancer Inst; 1976 Oct; 57(4):749-51. PubMed ID: 1003526
    [Abstract] [Full Text] [Related]

  • 5. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
    Krown SE, Hilal EY, Pinsky CM, Hirshaut Y, Wanebo HJ, Hansen JA, Huvos AG, Oettgen HF.
    Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
    [Abstract] [Full Text] [Related]

  • 6. Intralesional immunotherapy of melanoma with BCG.
    Rosenberg SA, Rapp HJ.
    Med Clin North Am; 1976 May; 60(3):419-30. PubMed ID: 1271887
    [Abstract] [Full Text] [Related]

  • 7. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS, Peters M.
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [Abstract] [Full Text] [Related]

  • 8. Treatment for melanoma of the lower extremity with intralesional injection of bacille Calmette Guérin and hyperthermic perfusion.
    Storm FK, Sparks FC, Morton DL.
    Surg Gynecol Obstet; 1979 Jul; 149(1):17-21. PubMed ID: 451822
    [Abstract] [Full Text] [Related]

  • 9. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
    de la Monte SM, Hutchins GM.
    Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
    [Abstract] [Full Text] [Related]

  • 10. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS, Mastrangelo MJ, Sulit H, Chee D, Yarbro JW, Prehn LM, Prehn RT.
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract] [Full Text] [Related]

  • 11. Intralesional BCG in the treatment of metastatic malignant melanoma.
    Mastrangelo MJ, Sulit HL, Prehn LM, Bornstein RS, Yarbro JW, Prehn RT.
    Cancer; 1976 Feb; 37(2):684-92. PubMed ID: 766947
    [Abstract] [Full Text] [Related]

  • 12. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU, Mavligit G, Reed R, Richman S, McBride CE, Hersh EM.
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract] [Full Text] [Related]

  • 13. Immunotherapy of malignancy in humans. Current status.
    Holmes EC, Eilber FR, Morton DL.
    JAMA; 1975 Jun 09; 232(10):1052-5. PubMed ID: 236402
    [Abstract] [Full Text] [Related]

  • 14. Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma.
    Nathanson L, Schoenfeld D, Regelson W, Colsky J, Mittelman A.
    Cancer; 1979 May 09; 43(5):1630-5. PubMed ID: 376098
    [Abstract] [Full Text] [Related]

  • 15. [Studies on the immune status of melanoma patients: cell-mediated immune reactions in intracutaneous and epicutaneous tests in the lymphocyte transformation test and the leukocyte-migration inhibition test before and during BCG immunotherapy (author's transl)].
    Knopf B, Wätzig V, Knöll B.
    Arch Geschwulstforsch; 1978 May 09; 48(8):722-8. PubMed ID: 753194
    [Abstract] [Full Text] [Related]

  • 16. [Immunotherapy of malignant melanoma (active specific and non-specific immune stimulation) (author's transl)].
    Kokoschka EM, Micksche M.
    Wien Klin Wochenschr; 1976 Nov 12; 88(21):690-6. PubMed ID: 1007279
    [Abstract] [Full Text] [Related]

  • 17. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
    Pinsky CM, Hirshaut Y, Wanebo HJ, Fortner JG, Miké V, Schottenfeld D, Oettgen HF.
    Ann N Y Acad Sci; 1976 Nov 12; 277(00):187-94. PubMed ID: 1069548
    [No Abstract] [Full Text] [Related]

  • 18. Intralesional immune therapy: methanol extraction residue of BCG or purified protein derivative.
    Lokich JJ, Garnick MB, Legg M.
    Oncology; 1979 Nov 12; 36(5):236-41. PubMed ID: 481845
    [Abstract] [Full Text] [Related]

  • 19. An in vitro method for assaying sensitivity to 2,4-dinitrochlorobenzene (DNCB) in man.
    Whitehead RH, Bolton PM, James SL, Roberts GM.
    Eur J Cancer (1965); 1974 Nov 12; 10(11):721-4. PubMed ID: 4469495
    [No Abstract] [Full Text] [Related]

  • 20. Results of administering B.C.G. to patients with melanoma.
    Grant RM, Mackie R, Cochran AJ, Murray EL, Hoyle D, Ross C.
    Lancet; 1974 Nov 09; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.